ENSPRYNG Now Available to Canadians with Neuromyelitis Optica Spectrum Disorder
source: pixabay.com

ENSPRYNG Now Available to Canadians with Neuromyelitis Optica Spectrum Disorder

Health Canada has recently granted market authorization to Hoffman La-Roche Limited for their neuromyelitis optica spectrum disorder treatment, ENSPRYNG. Canada is the first country to offer this medication, and hopefully…

Continue Reading ENSPRYNG Now Available to Canadians with Neuromyelitis Optica Spectrum Disorder
Study Finds That Neuromyelitis Optica Patients Could Face Weakened Bones and Fractures
source: pixabay.com

Study Finds That Neuromyelitis Optica Patients Could Face Weakened Bones and Fractures

According to a story from Neurology Advisor, a recent study has found that patients living with neuromyelitis optica spectrum disorder (NMOSD) are at an increased risk of experiencing bone loss,…

Continue Reading Study Finds That Neuromyelitis Optica Patients Could Face Weakened Bones and Fractures
TNF Inhibitors Increase Risk of Central Nervous System Inflammation for Patients with Autoimmune Disorders
mohamed_hassan / Pixabay

TNF Inhibitors Increase Risk of Central Nervous System Inflammation for Patients with Autoimmune Disorders

According to MedScape, tumor necrosis factor (TNF) inhibitors present severe issues for patients with autoimmune disorders. In particular, patients exposed to TNF inhibitors may experience inflammation throughout their central nervous…

Continue Reading TNF Inhibitors Increase Risk of Central Nervous System Inflammation for Patients with Autoimmune Disorders
Satralizumab May Lower Neuromyelitis Optica Spectrum Disorder Relapse in Patients
source: pixabay.com

Satralizumab May Lower Neuromyelitis Optica Spectrum Disorder Relapse in Patients

By Danielle Bradshaw from In The Cloud Copy It has been shown in a recently published trial that satralizumab could potentially reduce the risk of neuromyelitis optica spectrum disorder (NMOSD)…

Continue Reading Satralizumab May Lower Neuromyelitis Optica Spectrum Disorder Relapse in Patients
New Method Easily Distinguishes Between Multiple Sclerosis and Neuromyelitis Optica
Science!

New Method Easily Distinguishes Between Multiple Sclerosis and Neuromyelitis Optica

  Technological advancement throughout the world will ultimately lead to new ideas and strategies within the medical realm. As reported by Azo Sensors, a team of Brazilian researchers is already…

Continue Reading New Method Easily Distinguishes Between Multiple Sclerosis and Neuromyelitis Optica
The FDA is Developing, Approving, and Expediting Exciting New Therapies
source: pixabay.com

The FDA is Developing, Approving, and Expediting Exciting New Therapies

  Janet Woodcock, Director of the FDA’s Center for Drug Evaluation and Research (CDER) recently gave an interview to the publication FDA Voices about the agency’s approval in 2019 of a…

Continue Reading The FDA is Developing, Approving, and Expediting Exciting New Therapies
Research Team Offers Recommendations to Improve Personalized Care for Multiple Sclerosis Patients
source: pixabay.com

Research Team Offers Recommendations to Improve Personalized Care for Multiple Sclerosis Patients

A New Working Group A team of healthcare professionals from the Institute for Quality and Efficacy in Health Care, the Drug Commission of the German Medical Association, and the Charité…

Continue Reading Research Team Offers Recommendations to Improve Personalized Care for Multiple Sclerosis Patients
Marketing Applications for a Possible Neuromyelitis Optica Spectrum Disorder Drug Have Been Accepted in the US and EU
LhcCoutinho / Pixabay

Marketing Applications for a Possible Neuromyelitis Optica Spectrum Disorder Drug Have Been Accepted in the US and EU

According to a story from BioSpace, Chugai Pharmaceutical Co., Ltd. has recently announced that the Marketing Authorisation Application for the its drug satralizumab has been accepted by the European Medicines…

Continue Reading Marketing Applications for a Possible Neuromyelitis Optica Spectrum Disorder Drug Have Been Accepted in the US and EU

An Experimental Drug Could be Effective for Neuromyelitis Optica, Study Results Show

According to a story from Biotech 365, the biotechnology company Viela Bio announced the publication of critical results from a recent study that tested the company's investigational drug inebilizumab as…

Continue Reading An Experimental Drug Could be Effective for Neuromyelitis Optica, Study Results Show
FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug
mohamed_hassan / Pixabay

FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug

According to a press release from Maryland-based Viela Bio, the US Food and Drug Administration (FDA) recently agreed to review the Company's Biologics License Application for its neuromyelitis optica spectrum…

Continue Reading FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug

FDA Approves Soliris for Treatment of Neuromyelitis Optica Spectrum Disorder

According to a publication at Markets Insider, the Food and Drug Administration (FDA) recently approved Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder. The approval marks the first…

Continue Reading FDA Approves Soliris for Treatment of Neuromyelitis Optica Spectrum Disorder

Experimental Treatment for Neuromyelitis Optica Earns Breakthrough Therapy Designation

According to a story from BioSpace, the biotechnology company Viela Bio recently announced that the US Food and Drug Administration (FDA) has awarded an experimental therapy in development by the…

Continue Reading Experimental Treatment for Neuromyelitis Optica Earns Breakthrough Therapy Designation